Editors for Cancer Biology
Senior editors
-
Sean Morrison
Senior Editor
The Morrison laboratory studies the cellular and molecular mechanisms that regulate stem cell function in the nervous and hematopoietic systems. Dr Morrison obtained his BSc in biology and chemistry from Dalhousie University (1991), then completed a PhD in immunology at Stanford University (1996), and a postdoctoral fellowship in neurobiology at Caltech (1999). From 1999 to 2011, Dr Morrison was at the University of Michigan where he Directed their Center for Stem Cell Biology. Recently, Dr Morrison moved to the University of Texas Southwestern Medical Center where he is the founding Director of the new Children’s Research Institute. Dr Morrison’s laboratory studies the mechanisms that regulate stem cell self-renewal and stem cell aging, as well as the role these mechanisms play in cancer. Dr Morrison was a Searle Scholar (2000–2003), was named in Technology Review Magazine’s list of 100 young innovators (2002), received the Presidential Early Career Award for Scientists and Engineers (2003), the International Society for Hematology and Stem Cell’s McCulloch and Till Award (2007), the American Association of Anatomists Harland Mossman Award (2008), and a MERIT Award from the National Institute on Aging. Dr Morrison has also been active in public policy issues surrounding stem cells. For example, he has twice testified before Congress and was a leader in the successful “Proposal 2” campaign to protect stem cell research in Michigan’s state constitution.
- Expertise
- Cancer Biology
- Stem Cells and Regenerative Medicine
- Research focus
- tissue stem cells
- blood
- cancer biology
- hematopoietic system
- Competing interests statement
- Sean Morrison receives funding from the Howard Hughes Medical Institute, the National Institutes of Health, and the Cancer Prevention and Research Institute of Texas. In addition to being a Senior editor for eLife, he is a member of the editorial boards of Cell Stem Cell, the Journal of Experimental Medicine, the EMBO Journal, the Faculty of 1000, Current Opinion in Cell Biology, Cancer Cell, EMBO Reports, and Stem Cell Reports. He serves on the scientific advisory boards of the California Institute for Regenerative Medicine, the University of Washington Institute for Stem Cells and Regenerative Medicine, the University of California, Los Angeles Broad Stem Cell Research Center, and the Common Fund for the National Institutes of Health Center for Regenerative Medicine. He is President-Elect of the International Society for Stem Cell Research. He is a co-founder and shareholder in OncoMed Pharmaceuticals, a consultant and shareholder in G1 Therapeutics, a shareholder in Fate Therapeutics, and a consultant for Molecular Devices.
-
Aviv Regev
Senior Editor
Aviv Regev is a computational biologist who joined the Broad Institute as a core member and MIT as a faculty member in 2006. Her work investigates how complex molecular networks function and evolve in the face of genetic and environmental changes, over time-scales ranging from minutes to millions of years. Regev received her MSc from Tel Aviv University, studying biology, computer science, and mathematics in the Interdisciplinary Program for the Fostering of Excellence, where she undertook research in both theoretical and experimental biology. She received her PhD in computational biology from Tel Aviv University. Prior to joining the Broad Institute, Regev was a fellow at the Bauer Center for Genomics Research at Harvard University, where she developed new approaches to the reconstruction of regulatory networks and modules from genomic data. Regev is also an associate professor in the Department of Biology at MITâ¨and director of the Klarman Cell Observatory at the Broad. Regev is the Director of the Cell Circuits Program at the Broad and a lead principal investigator for the Center for Cell Circuits at the Broad Institute, a Center of Excellence in Genomic Science (CEGS). Regev has been a Howard Hughes Medical Institute (HHMI) Early Career Scientist since 2009, and was named a Howard Hughes Medical Institute (HHMI) Investigator in 2013. She is a recipient of the NIH Director’s Pioneer Award, a Sloan fellowship from the Sloan Foundation, the Overton Prize from the International Society for Computational Biology, and the Earl and Thressa Stadtman Scholar Award from the American Society for Biochemistry and Molecular Biology (ASBMB).
(Image Credit: Maria Nemchuk)
- Expertise
- Computational and Systems Biology
- Genetics and Genomics
- Chromosomes and Gene Expression
- Evolutionary Biology
- Cancer Biology
- Research focus
- systems biology
- molecular networks
- computational biology
- single cell genomics
- regulatory networks
- systems immunology
- gene regulation
- evolution
- Competing interests statement
- Aviv Regev receives funding from the Howard Hughes Medical Institute, the National Institutes of Health, and the Sloan Foundation. She is on the external advisory board of the San Diego Center for Systems Biology, the FAS Center for Systems Biology at Harvard, the Simons Institute for the Theory of Computing, the Jackson Laboratory, the European Molecular Biology Lab (EMBL), the SciLife Lab in Sweden, and ThermoFisher Scientific. She is on the advisory editorial board of Molecular Systems Biology and is an editorial board member of Genome Biology and Development. Regev is a consultant for Syros Phramaceuticals, GenePeeks, and CTIG (Cancer Therapeutics Innovation Group). Regev also worked for several years in the biotech industry in Israel, where she established and directed a bioinformatics research and development team at QBI, a functional genomics company.
-
Charles Sawyers
Senior Editor
Charles Sawyers is an Investigator of the Howard Hughes Medical Institute and the Director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center. His studies of BCR-ABL tyrosine kinase function in chronic myeloid leukemia, in collaboration with Brian Druker and Novartis, led to the development of the kinase inhibitor imatinib as primary therapy for CML. This was followed by his discovery that BCR-ABL kinase domain mutations confer imatinib resistance, and development of the second generation Abl kinase inhibitor dasatinib, in collaboration with Bristol Myers Squibb. Sawyers' current work in prostate cancer resulted in the novel antiandrogen enzalutamide (MDV3100), discovered in collaboration with University of California, Los Angeles chemist Michael Jung, which received FDA approval in 2012. Sawyers is a member of the National Academy of Sciences and the Institute of Medicine and co-recipient of the 2009 Lasker~DeBakey Clinical Medical Research Award.
- Expertise
- Cancer Biology
- Human Biology and Medicine
- Research focus
- oncology and translational medicine
- oncology
- translational medicine
- Competing interests statement
- Charles Sawyers receives research funding from the Howard Hughes Medical Institute, the National Cancer Institute, the Starr Cancer Consortium, Stand Up to Cancer, and the Prostate Cancer Foundation. He is President Elect of the American Association of Cancer Research and will serve as President from 2013–14. He is a Councilor of the American Association of Physicians (until 2017) and serves on the editorial boards of Cell and Cancer Cell, and as a scientific advisor to Agios, Aragon, Aveo, Housey Pharmaceuticals, Merck, Nextech, Pfizer, and Tracon.
-
Jeffrey Settleman
Senior Editor
Jeff Settleman is the Head of Oncology Research at Calico Life Sciences, an aging-focused biotechnology company in South San Francisco. His research is focused on cancer cell biology and therapeutics. He is particularly interested in mechanisms of drug resistance and the phenotypic heterogeneity within cell populations that drives tumor evolution. He received a Ph.D. degree in Genetics from Yale University in 1989, conducting thesis research under the mentorship of Dr. Dan Dimaio, and from 1989-1992 was a postdoctoral fellow at the Whitehead Institute for Biomedical Research at M.I.T. in Dr. Robert Weinberg’s laboratory. He joined the Harvard School of Medicine faculty in 1992, and was named the Laurel Schwartz Professor of Oncology at Harvard Medical School in 2008. He was also the Director of the Center for Molecular Therapeutics, the Scientific Director of the Massachusetts General Hospital Cancer Center, and the Leader of the Cancer Cell Biology program within the Dana Farber/Harvard Cancer Center. In 2010, Dr. Settleman transitioned from academia to industry, joining Genentech as the Senior Director of Discovery Oncology, where he oversaw efforts to identify and validate targets for oncology drug discovery and to discover predictive biomarkers for new cancer therapies.
- Expertise
- Cancer Biology
- Research focus
- cancer cell biology
- signal transduction
- tumor heterogeneity
- signaling
- epigenetics
Reviewing editors
-
Margaret Frame
University of Edinburgh, United Kingdom
- Expertise
- Cancer Biology
- Research focus
- cancer
- cell adhesion networks
- nodal tyrosine kinases
-
Martin Eilers
University of Würzburg, Germany
- Expertise
- Cancer Biology
- Research focus
- Myc proteins
- Myc function
- Targeting N-MYC/AURORA for tumor therapy
- Myc and Ubiquitin
- Experimental organism
- human
-
A. Thomas Look
Dana-Farber Cancer Institute, United States
- Expertise
- Cancer Biology
- Chromosomes and Gene Expression
- Human Biology and Medicine
- Research focus
- neuroblastoma
- acute leukemia
- hematopoietic malignancies
- cancer genetics
- Experimental organism
- human
- mouse
- zebrafish
-
Ian Tannock
Princess Margaret Cancer Centre, Canada
- Expertise
- Cancer Biology
- Human Biology and Medicine
- Research focus
- clinical trials
- tumour microenvironment
- cancer therapy
- clinical resistance to drugs
- Experimental organism
- human
-
Jody Rosenblatt
University of Utah, United States
- Expertise
- Cell Biology
- Human Biology and Medicine
- Cancer Biology
- Research focus
- apoptosis
- mitosis
- cell extrusion
- epithelial
- homeostasis
- morphogenesis
- cancer cell biology
-
Matthew G. Vander Heiden
Massachusetts Institute of Technology, United States
- Expertise
- Cancer Biology
- Human Biology and Medicine
- Research focus
- cancer metabolism
- cell metabolism
- metabolic biochemistry
- Experimental organism
- mouse
-
Beate Lichtenberger
Medical University of Vienna, Austria
- Expertise
- Cancer Biology
- Stem Cells and Regenerative Medicine
- Research focus
- Cancer-associated fibroblasts (CAFs)
- fibroblast-mediated skin pathologies
- skin cancer
- stem cell fate decisions
- Experimental organism
- human
- mouse
-
Kari Alitalo
University of Helsinki, Finland
- Expertise
- Cancer Biology
- Cell Biology
- Human Biology and Medicine
- Research focus
- cancer biology
- oncogenes
- angiogenesis
- vascular biology
-
Utpal Banerjee
University of California, Los Angeles, United States
- Expertise
- Cancer Biology
- Stem Cells and Regenerative Medicine
- Human Biology and Medicine
- Developmental Biology
- Research focus
- haematopoiesis
- cancer biology
- Experimental organism
- Drosophila
-
Xuetao Cao
Zhejiang University School of Medicine, China
- Expertise
- Cancer Biology
- Immunology and Inflammation
- Research focus
- immunology of apcs
- TLR signalling and immune regulation
- cancer immunotherapy and gene therapy
-
Irwin Davidson
Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS/INSERM/UDS, France
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Chromosomes and Gene Expression
- Research focus
- transcription
- chromatin
- cancer
-
Ralph J DeBerardinis
University of Texas Southwestern Medical Center, United States
- Expertise
- Cancer Biology
- Cell Biology
- Human Biology and Medicine
- Research focus
- cancer
- metabolism
- medicine
- genetics
- Experimental organism
- human
- mouse
-
Elisabetta Dejana
FIRC Institute of Molecular Oncology, Italy
- Expertise
- Cancer Biology
- Cell Biology
- Developmental Biology
- Research focus
- angiogenesis
- cell adhesion
- VE-cadherin
- vascular permeability
- vascular development and patterning
- endothelium
- blood brain barrier
-
Joaquin Espinosa
University of Colorado Denver School of Medicine, United States
- Expertise
- Cancer Biology
- Cell Biology
- Human Biology and Medicine
- Research focus
- apoptosis
- p53
- tumor suppressors
- cancer biology
-
Eduardo Franco
McGill University, Canada
- Expertise
- Cancer Biology
- Epidemiology and Global Health
- Human Biology and Medicine
- Microbiology and Infectious Disease
- Research focus
- human biology and medicine
- microbiology and infectious disease
- cancer epidemiology and prevention
- screening
- human papillomavirus infection
-
Michael R Green
University of Massachusetts Medical School, United States
- Expertise
- Cancer Biology
- Chromosomes and Gene Expression
- Human Biology and Medicine
- Research focus
- RNA splicing
- cancer molecular biology
-
Tony Hunter
Salk Institute for Biological Studies, United States
- Expertise
- Cancer Biology
- Cell Biology
- Research focus
- cell signaling and basic cancer biology
- signaling pathways in animal and human cells
- cell cycle
- phosphorylation
- protein modification
- cancer
-
Ross Levine
Memorial Sloan Kettering Cancer Center, United States
- Expertise
- Cancer Biology
- Research focus
- genetic basis of blood disorders
- myeloid malignancies
- myeloproliferative neoplasms
- leukemia
- Experimental organism
- human
-
Joan Massagué
Memorial Sloan Kettering Cancer Center, United States
- Expertise
- Cancer Biology
- Cell Biology
- Human Biology and Medicine
- Research focus
- signaling
- cell fate
- tumor heterogeneity
- metastasis
- Experimental organism
- human tissue
-
Martin McMahon
University of Utah, United States
- Expertise
- Cancer Biology
- Research focus
- metastatic melanoma
- lung cancer
- thyroid cancer
- Experimental organism
- mouse
- human
-
Maureen Murphy
The Wistar Institute, United States
- Expertise
- Cancer Biology
- Research focus
- p53
- genetics
- ferroptosis
- cell death
- melanoma
- heat shock proteins
-
Duojia Pan
UT Southwestern Medical Center, United States
- Expertise
- Cancer Biology
- Cell Biology
- Human Biology and Medicine
- Research focus
- signal transduction
- growth control
- cancer biology
- Experimental organism
- Drosophila
-
Alfonso Valencia
Barcelona Supercomputing Center, Spain
- Expertise
- Cancer Biology
- Computational and Systems Biology
- Research focus
- bioinformatics
- structural bioinformatics
- evodevo
- cancer genomics
- text mining
-
Maarten van Lohuizen
The Netherlands Cancer Institute, Netherlands
- Expertise
- Cancer Biology
- Research focus
- epigenetics
- cancer
- stem cells
- chromatin
-
Richard White
Memorial Sloan Kettering Cancer Center, United States
- Expertise
- Cancer Biology
- Developmental Biology
- Stem Cells and Regenerative Medicine
- Research focus
- cancer
- metastasis
- genetics
- melanocyte
- melanoma
- neural crest
- Experimental organism
- human
- zebrafish
